Literature DB >> 18697558

Sequential and simultaneous dual-isotope brain SPECT: comparison with PET for estimation and discrimination tasks in early Parkinson disease.

Cathryn M Trott1, Georges El Fakhri.   

Abstract

Parkinson disease (PD) is the second most frequently occurring cerebral degenerative disease, after Alzheimer disease. Treatments are available, but their efficacy is diminished unless they are administered in the early stages. Therefore, early identification of PD is crucial. In addition to providing perfectly registered studies, simultaneous 99mTc/123I imaging makes possible the assessment of pre- and postsynaptic neurotransmission functions under identical physiological conditions, while doubling the number of counts for the same total imaging time. These advantages are limited, however, by cross talk between the two radionuclides due to the close emission energies of 99mTc (140 keV) and 123I (159 keV). PET, on the other hand, provides good temporal and spatial resolution and sensitivity but usually requires the use of a single radionuclide. In the present work, the authors compared brain PET with sequential and simultaneous dual-isotope SPECT for the task of estimating striatal activity concentration and striatal size for a normal brain and two stages of early PD. Realistic Monte Carlo simulations of a time-of-flight PET scanner and gamma cameras were performed while modeling all interactions in the brain, collimator (gamma camera) and crystal (detector block in PET), as well as population biological variability of pre- and postsynaptic uptake. For SPECT imaging, we considered two values of system energy resolution and scanners with two and three camera heads. The authors used the Cramer-Rao bound, as a surrogate for the best theoretical performance, to optimize the SPECT acquisition energy windows and objectively compare PET and SPECT. The authors determined the discrimination performance between 500 simulated subjects in every disease stage as measured by the area under the ROC curve (AUC). The discrimination accuracy between a normal subject and a subject in the prodromal disease stage was AUC = 0.924 with PET, compared to 0.863 and 0.831 with simultaneous and sequential SPECT, respectively. The significant improvement in performance obtained with simultaneous dual-isotope SPECT compared to sequential imaging (p = 0.019) was due primarily to the increased number of counts detected and resulted in comparable performance when performing simultaneous SPECT on a two-head camera with 9.2% energy resolution to that obtained with sequential SPECT on a three-head camera with 6.2% energy resolution.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697558      PMCID: PMC2673561          DOI: 10.1118/1.2940605

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  23 in total

1.  The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease.

Authors:  P F Kao; K Y Tzen; T C Yen; C S Lu; Y H Weng; S P Wey; G Ting
Journal:  Nucl Med Commun       Date:  2001-02       Impact factor: 1.690

2.  [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.

Authors:  K Marek; R Innis; C van Dyck; B Fussell; M Early; S Eberly; D Oakes; J Seibyl
Journal:  Neurology       Date:  2001-12-11       Impact factor: 9.910

3.  Kinetic modeling of [99mTc]TRODAT-1: a dopamine transporter imaging agent.

Authors:  S A Kushner; W T McElgin; M P Kung; P D Mozley; K Plössl; S K Meegalla; M Mu; S Dresel; J M Vessotskie; N Lexow; H F Kung
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

4.  Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.

Authors:  A J Fischman; A A Bonab; J W Babich; E P Palmer; N M Alpert; D R Elmaleh; R J Callahan; S A Barrow; W Graham; P C Meltzer; R N Hanson; B K Madras
Journal:  Synapse       Date:  1998-06       Impact factor: 2.562

5.  Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability.

Authors:  N P Verhoeff; O Kapucu; E Sokole-Busemann; E A van Royen; A G Janssen
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

6.  Absolute activity quantitation in simultaneous 123I/99mTc brain SPECT.

Authors:  G El Fakhri; S C Moore; P Maksud; A Aurengo; M F Kijewski
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

7.  Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease.

Authors:  S Asenbaum; T Brücke; W Pirker; I Podreka; P Angelberger; S Wenger; C Wöber; C Müller; L Deecke
Journal:  J Nucl Med       Date:  1997-01       Impact factor: 10.057

8.  Quantitative SPECT leads to improved performance in discrimination tasks related to prodromal Alzheimer's disease.

Authors:  Georges El Fakhri; Marie Foley Kijewski; Marilyn S Albert; Keith A Johnson; Stephen C Moore
Journal:  J Nucl Med       Date:  2004-12       Impact factor: 10.057

9.  Test-retest variability and reliability of 123I-IBZM SPECT measurement of striatal dopamine D2 receptor availability in healthy volunteers and influence of iterative reconstruction algorithms.

Authors:  Ana M Catafau; Santiago Bullich; Mónica Danús; María M Penengo; Albert Cot; Sergio Abanades; Magí Farré; Javier Pavía; Domènec Ros
Journal:  Synapse       Date:  2008-01       Impact factor: 2.562

10.  Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.

Authors:  Dao-Ying Geng; Yu-Xin Li; Chi-Shing Zee
Journal:  Neurosurgery       Date:  2006-02       Impact factor: 4.654

View more
  2 in total

1.  Comparison of simultaneous and sequential SPECT imaging for discrimination tasks in assessment of cardiac defects.

Authors:  C M Trott; J Ouyang; G El Fakhri
Journal:  Phys Med Biol       Date:  2010-11-03       Impact factor: 3.609

2.  Dual tracer imaging of SPECT and PET probes in living mice using a sequential protocol.

Authors:  Sarah E Chapman; Justin M Diener; Todd A Sasser; Carlos Correcher; Antonio J González; Tony Van Avermaete; W Matthew Leevy
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.